Evidence map›Paper›PMID 24062699›Full record

ArticleFrontiers in psychiatry2013

Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding.

Shannon L Risacher, Yang Wang, Heather A Wishart, Laura A Rabin, Laura A Flashman, Brenna C McDonald, John D West, Robert B Santulli, Andrew J Saykin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 4 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. The Role of fMRI in Drug Development: An Update.Advances in neurobiology · 2023
    Article
  8. Article
  9. Muscarinic and Nicotinic Modulation of Memory but not Verbal Problem-solving.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. The role of fMRI in drug development.Drug discovery today · 2018
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Shannon L RisacherDepartment of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine , Indianapolis, IN , USA ; Indiana Alzheimer Disease Center, Indiana University School of Medicine , Indianapolis, IN , USA.
Yang Wang
Heather A Wishart
Laura A Rabin
Laura A Flashman
Brenna C McDonald
John D West
Robert B Santulli
Andrew J Saykin
Dartmouth–Hitchcock Medical Center · USIndiana University School of MedicineIndiana University – Purdue University Indianapolis · USThe Graduate Center, CUNY · US

Funding

Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Memory Circuitry in MCI and Early Alzheimer’s Disease Prodrome: Molecular DriversR01AG019771 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 2001 to 2021
$6.9M
NIA NIH HHS P30 AG010133NIA NIH HHS R01 AG019771
6 · The paper itself

Abstract

objectiveTo determine the physiological impact of treatment with donepezil (Aricept) on neural circuitry supporting episodic memory encoding in patients with amnestic mild cognitive impairment (MCI) using functional magnetic resonance imaging (fMRI).

methodsEighteen patients with MCI and 20 age-matched healthy controls (HC) were scanned twice while performing an event-related verbal episodic encoding task. MCI participants were scanned before treatment and after approximately 3 months on donepezil; HC were untreated but rescanned at the same interval. Voxel-level analyses assessed treatment effects on activation profiles in MCI patients relative to retest changes in non-treated HC. Changes in task-related connectivity in medial temporal circuitry were also evaluated, as were associations between brain activation, task-related functional connectivity, task performance, and clinical measures of cognition.

resultsAt baseline, the MCI group showed reduced activation during encoding relative to HC in the right medial temporal lobe (MTL; hippocampal/parahippocampal) and additional regions, as well as attenuated task-related deactivation, relative to rest, in a medial parietal lobe cluster. After treatment, the MCI group showed normalized MTL activation and improved parietal deactivation. These changes were associated with cognitive performance. After treatment, the MCI group also demonstrated increased task-related functional connectivity from the right MTL cluster seed region to a network of other sites including the basal nucleus/caudate and bilateral frontal lobes. Increased functional connectivity was associated with improved task performance.

conclusionPharmacologic enhancement of cholinergic function in amnestic MCI is associated with changes in brain activation and functional connectivity during episodic memory processing which are in turn related to increased cognitive performance. fMRI is a promising biomarker for assessing treatment related changes in brain function.

Indexed as

Alzheimer’s diseasedonepezil (Aricept)episodic encodingfunctional magnetic resonance imagingmild cognitive impairmenttask-related functional connectivity

Identifiers

PMID24062699
PMCPMC3775540
OpenAlexW2147339440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.